1Dietel M, Sers C. Personalized medicine and development of targeted therapies : the upcoming challenge for diagnostic molecular pathology. A review. Virchows Arch, 2006, 448 (6) :744-755. 被引量：1
2Watson MA, Perry A, Budhraja V, et al. Gene expression profiling with oligonucleotide microarrays distinguishes World Health Organization grade of oligodendrogliomas. Cancer Res, 2001,61 (5) : 1825-1829. 被引量：1
3Bhattacharjee A, Richards WG, Staunton J, et al. Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses. Proc Natl Acad Sci U S A, 2001,98(24) :13790-13795. 被引量：1
4Giordano TJ, Shedden KA, Schwartz DR, et al. Organ-specific molecular classification of primary lung, colon, and ovarian adenocarcinomas using gene expression profiles. Am J Pathol, 2001, 159(4) :1231-1238. 被引量：1
5van't Veer L J, Dai H, van de Vijver MJ, et al. Expression profiling predicts outcome in breast cancer. Breast Cancer Res, 2003,5( 1 ) :57-58. 被引量：1
9Fierz W. Challenge of personalized health care: to what extent is medicine already individualized and what are the future trends? Med Sci Monit, 2004,10(5) :RA111-RA123. 被引量：1
10Ross JS, Ginsburg GS. The integration of molecular diagnostics with therapeutics. Implications for drug development and pathology practice. Am J Clin Pathol, 2003,119( 1 ) :26-36. 被引量：1
2Jacobs TW,Gown AM,Yaziji H,et al.Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer.J Clin Oncol,1999,17:1974-1982. 被引量：1
3Zhao J,Wu R,Au A,et al.Determination of HER2 gene amplification by chromogenic in situ hybridization (CISH) in archival breast carcinoma.Mod Pathol,2002,15:657-665. 被引量：1
4Isola J,Tanner M,Forsyth A,et al.Interlaboratory comparison of HER-2 oncogene amplification as detected by chromogenic and fluorescence in situ hybridization.Clin Cancer Res,2004,10:4793-4798. 被引量：1
5Amould L,Denoux Y,MacGrogan G,et al.Agreement between chromogenic in situ hybridisation (CISH) and FISH in the determination of HER2 status in breast cancer.Br J Cancer,2003,88:1587-1591. 被引量：1
6Yaziji H,Goldstein LC,Barry TS,et al.HER-2 testing in breast cancer using parallel tissue-based methods.JAMA,2004,291:1972-1977. 被引量：1
7Press MF,Santer G,Bernstein L,et al.Diagnostic evaluation of HER-2 as a molecular target:an assessment of accuracy and reproducibility of laboratory testing in large,prospective,randomized clinical trials.Clin Cancer Res,2005,11:6598-6607. 被引量：1
8Dolan M,Snover D.Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice.Am J Clin Pathol,2005,123:766-770. 被引量：1
9Lan C,Liu JM,Liu TW,erb-b2 amplification by fluorescence in situ hybridization in breast cancer specimens read as 2 + in immunohistochemical analysis.Am J Clin Pathol,2005,124:97-102. 被引量：1
10Merola R,Mottolese M,Orlandi G,et al.Analysis of aneusomy level and HER-2 gene copy number and their effect on amplification rate in breast cancer specimens read as 2 + in immunohistochemical analysis.Eur J Cancer,2006,42:1501-1506. 被引量：1
